N
Novavax
Late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases
About Novavax
Novavax is a biotechnology company focused on developing innovative vaccines to address a broad range of infectious diseases. Utilizing proprietary recombinant nanoparticle vaccine technology, Novavax creates vaccine candidates that efficiently respond to both known and emerging disease threats. The company also develops immune-stimulating saponin-based adjuvants through its wholly-owned Swedish subsidiary, Novavax AB, which enhance immune responses and have been well tolerated in multiple clinical trials. Novavax primarily serves global healthcare markets, including governments and healthcare providers, aiming to mitigate urgent public health crises such as pandemics. The business model revolves around research and development, clinical trials, and large-scale manufacturing of vaccine antigens and adjuvants, funded by partnerships and grants, such as those from CEPI. Revenue is generated through the sale of vaccines and adjuvants, as well as through licensing agreements and government contracts.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1987
- Headquarters
- Gaithersburg, United States
- Listing
- IPO 1995
- Employees
- 937
- Open positions
- 3
- Dealroom signal
- 30.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2013
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Aug 2025 | $225M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | May 2024 | $70M | $1.4B | Sanofi | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Novavax is 420K monthly website visits, up 162.5% over the last three months. Novavax's team declined 31.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Bill & Melinda Gates Foundation
Coalition for Epidemic Preparedness
United States Government
Series B and later2 investors entered at this stage
Foresite Capital
Sanofi
Other known investors4 additional known investors
HHS Administration for Strategic Preparedness and Response- PPProspect Venture Partners
Shah Capital
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novavax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novavax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.